The Waning Of The Blockbuster Drug
The Waning Of The Blockbuster Drug
“What’s promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma “
Financial Snapshot For September 2004
Financial Snapshot For September 2004
In Need Of A Boost
Beleaguered Merck looks to future
Beleaguered Merck looks to future
“A week after saying it was withdrawing its $2.5 billion arthritis drug Vioxx from the market and losing a quarter of its stock market value as a result, Merck & Co. will try to dodge the storm clouds and turn its attention tomorrow to a brighter subject with the official opening of its Boston research lab.”
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments